Ophthalmology · Orlando, FL
NPI
1396745105
Since 2005
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
95 Columbia St
Orlando, FL, 32806
Phone (407) 849-9621
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.5M
68,307 services
Medicare patients, 2024
2,149
Average age 79
Drug cost, 2024
$529K
2,188 prescriptions
Company payments, 2025
$838
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elia C Mavrofrides was code J2777 (injection, faricimab-svoa, 0.1 mg), 36,720 times for 107 patients. In total Elia C Mavrofrides billed 68,307 services in 50 codes, and Medicare paid $6.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2777 Injection, faricimab-svoa, 0.1 mg | Office | 36,720 | 107 | $27.37 | $1.0M |
| J2781 Injection, pegcetacoplan, intravitreal, 1 mg | Office | 5,880 | 76 | $116.35 | $684K |
| J0177 Injection, aflibercept hd, 1 mg | Office | 4,720 | 149 | $263.67 | $1.2M |
| 92134 Computerized Ophthalmic Imaging | Office | 3,059 | 1,177 | $29.30 | $90K |
| 67028 Intravitreal Injection | Office | 3,053 | 752 | $96.69 | $295K |
| J0178 Injection, aflibercept, 1 mg | Office | 2,660 | 325 | $649.18 | $1.7M |
| 92250 Angiography | Office | 2,064 | 1,805 | $25.85 | $53K |
| Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 1,940 | 87 | $181.65 | $352K |
| 99213 Office E&M - Established | Office | 1,692 | 1,112 | $61.66 | $104K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 1,455 | 317 | $48.30 | $70K |
| 92014 Ophthalmological E&M | Office | 1,087 | 1,048 | $86.70 | $94K |
| J2782 Injection, avacincaptad pegol, 0.1 mg | Office | 1,040 | 13 | $86.35 | $90K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 534 | 264 | $36.57 | $20K |
| 92202 Ophthalmological E&M | Office | 307 | 299 | $10.28 | $3,157 |
| J7312 Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 287 | 25 | $150.51 | $43K |
By year: 2022 $5.4M for 36,925 services; 2023 $6.2M for 66,858 services; 2024 $6.5M for 68,307 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elia C Mavrofrides prescribed most often to Medicare patients was Prednisolone Acetate, with 513 prescriptions and refills. In total Elia C Mavrofrides wrote 2,188 Medicare prescriptions that cost $529K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisolone Acetate Generic | 513 | 944 | 254 | $21K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 219 | 544 | 92 | $3,416 |
| Latanoprost Generic | 201 | 329 | 62 | $1,791 |
| Timolol Maleate Generic | 185 | 350 | 65 | $2,029 |
| Brimonidine Tartrate Generic | 116 | 240 | 48 | $2,397 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 109 | 110 | 98 | $1,136 |
| Eylea Aflibercept | 96 | 96 | 25 | $224K |
| Ketorolac Tromethamine Generic | 79 | 118 | 35 | $2,905 |
| Loteprednol Etabonate Generic | 70 | 122 | 28 | $14K |
| Difluprednate Generic | 53 | 65 | 15 | $5,502 |
| Methazolamide Generic | 46 | 69 | Under 11 | $4,655 |
| Dorzolamide Hcl Generic | 45 | 118 | 21 | $651 |
| Lumigan Bimatoprost | 28 | 43 | 11 | $11K |
| Prolensa Bromfenac Sodium | 28 | 39 | Under 11 | $9,983 |
| Combigan Brimonidine Tartrate/Timolol | 25 | 28 | Under 11 | $7,001 |
Brand drugs: 1,035 claims; generic drugs: 1,153 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elia C Mavrofrides $838 ($838 in general payments such as food, travel and fees) from 8 companies. The largest payer was Astellas Pharma US Inc with $182.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.